Jennifer Lachey - Jun 14, 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Jun 14, 2022
Transactions value $
$2,820
Form type
4
Date filed
6/14/2022, 06:57 PM
Previous filing
May 13, 2022
Next filing
Jul 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $2.82K +9.4K +10.97% $0.30* 95.1K Jun 14, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -9.4K -14.22% $0.00 56.7K Jun 14, 2022 Common Stock 9.4K $0.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.